Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters
- PMID: 35545915
- DOI: 10.17235/reed.2022.8902/2022
Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters
Abstract
The current edition of the journal features a Spanish, nationwide, multi-institutional study by Gomez Bravo MA et al. exploring the advantages of everolimus (EVR)-facilitated tacrolimus (TAC) minimization versus TAC in combination with mycophenolate mofetil (MMF) after liver transplantation (LT).
Comment on
-
Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.Rev Esp Enferm Dig. 2022 Jun;114(6):335-342. doi: 10.17235/reed.2022.8549/2021. Rev Esp Enferm Dig. 2022. PMID: 35469409 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
